Determination of the effect of broccoli sprouts on inflammation in patients with diabetes

Determination of the effect of broccoli sprouts on pro- and anti- inflammatory markers in serum of patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013070810190N4

Enrollment

Registered

2013-07-17

Start date

2014-01-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes.

Interventions

Intervention 1: 10 g per day dried broccoli sprouts. Broccoli sprouts are an agricultural product cultivated by Agriculture Division in Shiraz University. Sprouts are consumed once per day for two mon

Treatment - Drugs

Placebo

10 g per day dried broccoli sprouts. Broccoli sprouts are an agricultural product cultivated by Agriculture Division in Shiraz University. Sprouts are consumed once per day for two months. Participant

10 g/day corn starch colored with spinach powder. Participants are asked to consume the starch with yogurt or other dishes.

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion: Patients with type 2 diabetes with at least 3 years from the onset of the disease. Exclusion: Insulin therapy, taking especial medications such as hormones, hypoglycemic agents, and lipid lowering medications, vitamin and iron supplements, vitamin K antagonists, those with nephropathy, neuropathy, and cardiovascular disease, liver disease, cancers, autoimmune and inflammatory diseases, pregnant and lactating women, smokers, and those on especial diets, and those who make major changes in their diet during intervention.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
C reactive protein. Timepoint: At the beginning of study and at the end of intervention. Method of measurement: Biochemical analysis.;Tumor necrosis factor-alpha. Timepoint: At the beginning of study and at the end of intervention. Method of measurement: Biochemical analysis.;Interleukin-6. Timepoint: At the beginning of study and at the end of intervention. Method of measurement: Biochemical analysis.	—

Measure

Time frame

C reactive protein. Timepoint: At the beginning of study and at the end of intervention. Method of measurement: Biochemical analysis.;Tumor necrosis factor-alpha. Timepoint: At the beginning of study and at the end of intervention. Method of measurement: Biochemical analysis.;Interleukin-6. Timepoint: At the beginning of study and at the end of intervention. Method of measurement: Biochemical analysis.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: At the beginning and at the end of study. Method of measurement: Weighing.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Masoumeh Akhlaghi

Shiraz University of Medical Sciences

akhlaghi_m@sums.ac.ir+98 71 1725 7288

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026